NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free WINT Stock Alerts $5.30 +0.07 (+1.34%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$5.20▼$5.7250-Day Range$5.07▼$7.8352-Week Range$4.78▼$35.10Volume43,455 shsAverage Volume19,681 shsMarket Capitalization$2.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Windtree Therapeutics alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Windtree Therapeutics Stock (NASDAQ:WINT)Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.Read More WINT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WINT Stock News HeadlinesApril 22, 2024 | bizjournals.comWindtree Therapeutics is dangerously low on cashApril 21, 2024 | msn.comWindtree Therapeutics Announces Reverse Stock Split in Strategy to Boost Market ComplianceApril 30, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.April 20, 2024 | americanbankingnews.comWindtree Therapeutics Stock Scheduled to Reverse Split on Monday, April 22nd (NASDAQ:WINT)April 18, 2024 | msn.comWhy Windtree Therapeutics (WINT) Stock Is Getting HammeredApril 18, 2024 | globenewswire.comWindtree Therapeutics Announces Reverse Stock SplitApril 17, 2024 | finance.yahoo.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 17, 2024 | globenewswire.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 30, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.April 9, 2024 | finanznachrichten.deWindtree Therapeutics: Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingApril 8, 2024 | globenewswire.comWindtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingFebruary 2, 2024 | msn.comWindtree Therapeutics Seeks Strategic Alternatives with Ladenburg ThalmannFebruary 1, 2024 | finance.yahoo.comWindtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a ResearchJanuary 31, 2024 | bizjournals.comWindtree Therapeutics hires investment bank to explore M&A optionsJanuary 31, 2024 | finance.yahoo.comWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesJanuary 29, 2024 | benzinga.comWindtree Therapeutics – This Biotech Inks License Deal For Lead CandidateJanuary 26, 2024 | finanznachrichten.deWindtree Therapeutics Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 26, 2024 | finance.yahoo.comWindtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | benzinga.comWindtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | finance.yahoo.comWindtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyJanuary 24, 2024 | money.usnews.comWindtree Therapeutics IncJanuary 18, 2024 | msn.comWindtree and Lee’s sign licence deal for heart failure therapyJanuary 18, 2024 | finance.yahoo.comUp To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater ChinaJanuary 17, 2024 | bizjournals.comWindtree Therapeutics signs drug licensing deal valued at up to $138M with Chinese drug companyJanuary 17, 2024 | finance.yahoo.comWindtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific RegionJanuary 4, 2024 | markets.businessinsider.comHold Rating on Windtree Therapeutics Pending Key Istaroxime StudiesJanuary 3, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Windtree Therapeutics (WINT) with Neutral RecommendationSee More Headlines Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today4/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:WINT CUSIPN/A CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($143.8850) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-275.06% Return on Assets-56.28% Debt Debt-to-Equity Ratio4.42 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book0.52Miscellaneous Outstanding Shares510,000Free Float508,000Market Cap$2.70 million OptionableNot Optionable Beta0.61 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Craig E. Fraser (Age 59)Chairman, President, CEO & Interim Principal Officer Comp: $553.75kDr. Steven G. Simonson (Age 65)Senior VP & Chief Medical Officer Comp: $446.1kMr. Eric L. Curtis M.B.A. (Age 56)Senior VP & COO Comp: $526.25kMs. Jamie McAndrew (Age 43)VP, Controller, Chief Accounting Officer & Corporate Secretary Mr. George Cox (Age 72)Vice President of Technical Operations Dr. Pratap ParuchuruExecutive Director of Clinical DevelopmentMs. Tracy RarickHead of Operations & Program ManagementMore ExecutivesKey CompetitorsSurrozenNASDAQ:SRZNMiNK TherapeuticsNASDAQ:INKTApplied Genetic TechnologiesNASDAQ:AGTCPluriNASDAQ:PLURAchilles TherapeuticsNASDAQ:ACHLView All CompetitorsInsidersCraig FraserBought 138 shares on 9/26/2023Total: $2,235.60 ($16.20/share)View All Insider Transactions WINT Stock Analysis - Frequently Asked Questions Should I buy or sell Windtree Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" WINT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WINT, but not buy additional shares or sell existing shares. View WINT analyst ratings or view top-rated stocks. How have WINT shares performed in 2024? Windtree Therapeutics' stock was trading at $12.9420 on January 1st, 2024. Since then, WINT shares have decreased by 59.0% and is now trading at $5.30. View the best growth stocks for 2024 here. Are investors shorting Windtree Therapeutics? Windtree Therapeutics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 2,600 shares, a decrease of 93.5% from the March 31st total of 39,700 shares. Based on an average daily trading volume, of 15,600 shares, the days-to-cover ratio is currently 0.2 days. View Windtree Therapeutics' Short Interest. When is Windtree Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our WINT earnings forecast. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) announced its quarterly earnings data on Tuesday, April, 16th. The company reported ($13.31) earnings per share (EPS) for the quarter. When did Windtree Therapeutics' stock split? Windtree Therapeutics's stock reverse split on the morning of Monday, April 22nd 2024. The 1-18 reverse split was announced on Monday, April 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WINT) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
